Planta Med 2018; 84(18): 1372-1379
DOI: 10.1055/a-0651-8141
Natural Product Chemistry and Analytical Studies
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Triterpenoids from Momordica balsamina with a Collateral Sensitivity Effect for Tackling Multidrug Resistance in Cancer Cells

Cátia Ramalhete
1   Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
2   ATLÂNTICA – Escola Universitária de Ciências Empresariais, Saúde, Tecnologias e Engenharia, Oeiras, Portugal
Silva Mulhovo
3   Centro de Estudos Moçambicanos e de Etnociências, Faculty of Natural Sciences and Mathematics, Pedagogical University, Maputo, Mozambique
Hermann Lage†
4   Institute of Pathology, University Hospital Charité, Berlin, Germany
5   Department of Pathology, Vivantes Clinics, Berlin, Germany
Maria-José U. Ferreira
1   Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
› Author Affiliations
Further Information

Publication History

received 27 March 2018
revised 05 June 2018

accepted 22 June 2018

Publication Date:
11 July 2018 (online)


The collateral sensitivity effect is among the most promising strategies for overcoming multidrug resistance in cancer. In this work, 28 cucurbitane-type triterpenoids (128), previously isolated from the African medicinal plant Momordica balsamina and its derivatives, were evaluated for their collateral sensitivity effect on three different human cancer entities, gastric (EPG85-257), pancreatic (EPP85-181), and colon (HT-29), each with two different multidrug-resistant variants. One was selected for its resistance to daunorubicin (EPG85-257RDB, EPP85-181RDB, HT-29RDB) and the other was selected for its resistance to mitoxantrone (EPG85-257RNOV, EPP85-181RNOV, HT-29RNOV). On gastric cell lines, the best results were obtained for compounds 3 and 10, which exhibited a collateral sensitivity effect together with high antiproliferative activity. In turn, on colon cancer cell lines, the best multidrug resistance-selective antiproliferative effects were observed for derivatives 11, 13, and 15, which showed collateral sensitivity effects against both resistant variants. Compounds 11 and 3 were also the most selective against the multidrug resistance pancreatic cells lines. Some compounds, such 6, 10, 11 and 15, were previously found to be strong P-glycoprotein modulators, thus highlighting their potential as promising leads for overcoming multidrug resistance in cancer cells.

Supporting Information

  • References

  • 1 Szakács G, Hall MD, Gottesman MM, Boumendjel A, Kachadourian R, Day BJ, Baubichon-Cortay H, Di Pietro A. Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev 2014; 114: 5753-5774
  • 2 Gottesman MM, Lavi O, Hall MD, Gillet JP. Toward a better understanding of the complexity of cancer drug resistance. Annu Rev Pharmacol Toxicol 2016; 56: 85-102
  • 3 Lagas JS, van Waterschoot RAB, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 2010; 9: 319-326
  • 4 Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MAJ, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JHM. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 2008; 7: 2280-2287
  • 5 Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Updat 2005; 8: 15-26
  • 6 Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 2013; 31: 1397-1407
  • 7 Klukovits A, Krajcsi P. Mechanisms and therapeutic potential of inhibiting drug efflux transporters. Expert Opin Drug Metab Toxicol 2015; 11: 907-920
  • 8 Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat 2012; 15: 98-105
  • 9 Thakur GS, Bag M, Sanodiya BS, Bhadouriya P, Debnath M, Prasad GB, Bisen PS. Momordica balsamina: a medicinal and neutraceutical plant for health care management. Curr Pharm Biotechnol 2009; 10: 667-682
  • 10 Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep 2005; 22: 386-399
  • 11 Dandawate PR, Subramaniam D, Padhye SB, Anant S. Bitter melon: a panacea for inflammation and cancer. Chin J Nat Med 2016; 14: 81-100
  • 12 Ramalhete C, Molnár J, Mulhovo S, Rosário VE, Ferreira MJU. New potent P-glycoprotein modulators with the cucurbitane scaffold and their synergistic interaction with doxorubicin on resistant cancer cells. Bioorg Med Chem 2009; 17: 6942-6951
  • 13 Ramalhete C, Mulhovo S, Molnar J, Ferreira MJU. Triterpenoids from Momordica balsamina: Reversal of ABCB1-mediated multidrug resistance. Bioorg Med Chem 2016; 24: 5061-5067
  • 14 Ramalhete C, Spengler G, Martins A, Martins M, Viveiros M, Mulhovo S, Ferreira MJU, Amaral L. Inhibition of efflux pumps in methicillin-resistant Staphylococcus aureus and Enterococcus faecalis resistant strains by triterpenoids from Momordica balsamina . Int J Antimicrob Agents 2011; 37: 70-74
  • 15 Reis MA, Ahmed OB, Spengler G, Molnár J, Lage H, Ferreira MJU. Exploring jolkinol D derivatives to overcome multidrug resistance in cancer. J Nat Prod 2017; 80: 1411-1420
  • 16 Reis MA, Ahmed OB, Spengler G, Molnár J, Lage H, Ferreira MJU. Jatrophane diterpenes and cancer multidrug resistance – ABCB1 efflux modulation and selective cell death induction. Phytomedicine 2016; 23: 968-978
  • 17 Reis MA, Paterna A, Ferreira RJ, Lage H, Ferreira MJU. Macrocyclic diterpenes resensitizing multidrug resistant phenotypes. Bioorg Med Chem 2014; 22: 3696-3702
  • 18 Paterna A, Kincses A, Spengler G, Mulhovo S, Molnár J, Ferreira MJU. Dregamine and tabernaemontanine derivatives as ABCB1 modulators on resistant cancer cells. Eur J Med Chem 2017; 128: 247-257
  • 19 Ferreira MJU, Duarte N, Reis M, Madureira AM, Molnár J. Euphorbia and Momordica metabolites for overcoming multidrug resistance. Phytochem Rev 2014; 13: 915-935
  • 20 Matos AM, Reis M, Duarte N, Spengler G, Molnár J, Ferreira MJU. Epoxylathyrol derivatives: modulation of ABCB1-mediated multidrug resistance in human colon adenocarcinoma and mouse T-lymphoma cells. J Nat Prod 2015; 78: 2215-2228
  • 21 Ramalhete C, da Cruz FP, Lopes D, Mulhovo S, Rosário VE, Prudêncio M, Ferreira MJU. Triterpenoids as inhibitors of erythrocytic and liver stages of Plasmodium infections. Bioorg Med Chem 2011; 19: 7474-7481
  • 22 Ramalhete C, Lopes D, Mulhovo S, Molnár J, Rosário VE, Ferreira MJU. New antimalarials with a triterpenic scaffold from Momordica balsamina . Bioorg Med Chem 2010; 18: 5254-5260
  • 23 Ramalhete C, Mansoor TA, Mulhovo S, Molnár J, Ferreira MJU. Cucurbitane-type triterpenoids from the African plant Momordica balsamina . J Nat Prod 2009; 72: 2009-2013
  • 24 Ramalhete C, Lopes D, Molnár J, Mulhovo S, Rosário VE, Ferreira MJU. Karavilagenin C derivatives as antimalarials. Bioorg Med Chem 2011; 19: 330-338
  • 25 Duarte N, Lage H, Abrantes M, Ferreira MJU. Phenolic compounds as selective antineoplasic agents against multidrug-resistant human cancer cells. Planta Med 2010; 76: 975-980
  • 26 Lage H, Duarte N, Coburger C, Hilgeroth A, Ferreira MJU. Antitumor activity of terpenoids against classical and atypical multidrug resistant cancer cells. Phytomedicine 2010; 17: 441-448
  • 27 Hilgeroth A, Baumert C, Coburger C, Seifert M, Krawczyk S, Hempel C, Neubauer F, Krug M, Molnár J, Lage H. Novel structurally varied N-alkyl 1,4-dihydropyridines as ABCB1 inhibitors: structure-activity relationships, biological activity and first bioanalytical evaluation. Med Chem 2013; 9: 487-493
  • 28 Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 2009; 30: 546-556
  • 29 Lage H. Proteomic approaches for investigation of therapy resistance in cancer. Proteomics. Clin Appl 2009; 3: 883-911
  • 30 Lage H, Aki-Sener E, Yalcin I. High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drug. Int J Cancer 2006; 119: 213-220